Intravenous Tapentadol in Post-Bunionectomy Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Grünenthal GmbH
ClinicalTrials.gov Identifier:
NCT01435577
First received: September 15, 2011
Last updated: June 24, 2013
Last verified: June 2013
  Purpose

The purpose of this trial is to established the safety and efficacy of multiple dose treatment with tapentadol IV in an adult population with moderate to severe pain following bunionectomy.


Condition Intervention Phase
Bunion
Pain
Drug: Tapentadol
Drug: Matching Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Parallel Group, Multicenter Trial to Evaluate the Efficacy and Safety of Multiple Dose Administration of an Intravenous Formulation of Tapentadol in the Treatment of Acute Pain Following Bunionectomy.

Resource links provided by NLM:


Further study details as provided by Grünenthal GmbH:

Primary Outcome Measures:
  • Sum of Pain Intensity Differences (SPID 24) [ Time Frame: Baseline value; up to 24 hours after first study drug administration ] [ Designated as safety issue: No ]
    Pain Intensity assessed at predefined time points (at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours after first drug administration) over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates "no pain" and a score of ten indicates "pain as bad as you can imagine". Pain Intensity Differences at each predefined time point (calculated as post-baseline NRS values - baseline NRS values) were analyzed. Negative SPID24 values indicate a decrease in pain intensity and positive values indicate an increase in pain intensity since baseline.


Secondary Outcome Measures:
  • Mean Pain Intensity Scores at Fixed Time Points [ Time Frame: Baseline; up to 48 hours ] [ Designated as safety issue: No ]
    The mean pain intensity at fixed time points in the trial for all participants is listed. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.

  • Pain Intensity Differences at Fixed Time Points [ Time Frame: Starting at 15 minutes and up to 48 hours after first drug administration ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline pain intensity (prior to the first dose) and the pain intensity at the time. A negative number indicates a decrease in pain in the whole treatment group. The greater the negative pain intensity difference value the greater the pain relief in the treatment arm. A score of 0 indicates that there has been no change in pain in a treatment group. A positive value indicates an increase in pain in the treatment group.

  • Patient Global Impression of Change After 12 Hours of Treatment [ Time Frame: Baseline value to 12 hours after first study drug administration ] [ Designated as safety issue: No ]
    In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).

  • Patients Global Impression of Change After 24 Hours of Treatment [ Time Frame: Baseline value to 24 hours after study drug administration ] [ Designated as safety issue: No ]
    In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).

  • Patient Global Impression of Change After 48 Hours of Treatment [ Time Frame: Baseline value to 48 hours after first study drug administration ] [ Designated as safety issue: No ]
    In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).

  • Sum of Pain Intensity Differences After 60 Minutes [ Time Frame: Baseline value to 60 minutes after first study drug administration ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 60 minutes was calculated. If the value is negative then the baseline pain intensity was greater than the pain intensity measured after dosing.

  • Sum of Pain Intensity Differences After 4 Hours [ Time Frame: Baseline value to 4 hours after first study drug intake ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 4 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).

  • Sum of Pain Intensity Differences After 8 Hours [ Time Frame: Baseline value to 8 hours after first study drug administration ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 8 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).

  • Sum of Pain Intensity Differences After 12 Hours [ Time Frame: Baseline value to 12 hours after first study drug administration ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 12 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).

  • Sum of Pain Intensity Differences After 48 Hours [ Time Frame: Baseline value to 48 hours after first study drug administration ] [ Designated as safety issue: No ]
    Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 60 minutes was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).

  • Number of Participants With 30% Response After 12 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 12 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participant response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 12 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.

  • Number of Participants With 30% Response After 24 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 24 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participant response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 24 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.

  • Number of Participants With 30% Response After 48 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 48 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participants response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 48 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.

  • Number of Participants With 50% Response After 12 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 12 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 12 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.

  • Number of Participants With 50% Response After 24 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 24 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 24 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.

  • Number of Participants With 50% Response After 48 Hours, Based on Pain Intensity Scores [ Time Frame: Baseline value to 48 hours after first study drug administration ] [ Designated as safety issue: No ]
    Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 48 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.

  • Time to First Rescue Medication [ Time Frame: up to 48 hours ] [ Designated as safety issue: No ]
    The median time to first rescue medication intake (600 mg ibuprofen) in hours.

  • Time to Perceptible Pain Relief [ Time Frame: up to 48 hours ] [ Designated as safety issue: No ]
    When the participant began to feel any pain-relieving effect after the administration of the first dose they were requested to stop the first stopwatch. The time was noted. This measured when the participant first felt any difference in the pain.

  • Time to Meaningful Pain Relief [ Time Frame: up to 48 hours ] [ Designated as safety issue: No ]
    The participant was instructed to stop the stopwatch when they had meaningful pain relief. That is, when the pain relief made a real difference, after the first drug administration.

  • Pharmacokinetic Concentrations of Tapentadol [ Time Frame: 15 minutes to 20 hours after first drug administration ] [ Designated as safety issue: No ]
    Tapentadol concentrations were measured in participants in the tapentadol treatment arm. Serum was analyzed by means of liquid chromatography coupled to tandem mass spectrometry with a lower limit of quantification (LLOQ) at 0.2 ng/mL.

  • Pharmacokinetic Concentrations of Tapentadol-O-glucuronide [ Time Frame: 15 minutes to 20 hours after first drug administration ] [ Designated as safety issue: No ]
    Tapentadol-O-glucuronide is the metabolite of tapentadol. Metabolites are sometimes referred to as "breakdown products". The body alters the administered medication to a metabolite so that can be more easily or quickly removed from the body. Tapentadol-O-glucuronide concentrations were measured in participants in the tapentadol treatment arm. Serum was analyzed by means of liquid chromatography coupled to tandem mass spectrometry with a lower limit of quantification (LLOQ) at 0.2 ng/mL.

  • Mean Pain Intensity Scores at Relative Time- Tapentadol Randomized Participants [ Time Frame: Baseline; for the first 6 administrations ] [ Designated as safety issue: No ]
    The pain intensity at the relative time points are the pain intensity before and one hour after study drug administration. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.

  • Mean Pain Intensity Scores at Relative Time - Matching Placebo Randomized Participants [ Time Frame: Baseline; for the first 6 administrations ] [ Designated as safety issue: No ]
    The pain intensity at the relative time points are the pain intensity before and one hour after study drug administration. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.


Enrollment: 177
Study Start Date: September 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tapentadol intravenous
Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
Drug: Tapentadol
30 mg per administration, maximum 12 administrations over 48 hours
Other Name: Palexia, Nucynta
Placebo Comparator: Matching placebo intravenous
Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
Drug: Matching Placebo
Maximum 12 administrations over 48 hours

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Scheduled to undergo primary unilateral first metatarsal bunionectomy
  • Female patients must be postmenopausal, surgically sterile, or practicing an effective method of birth control if they are sexually active
  • Qualifying pain intensity (within a maximum of 5 hours after the last surgical stitch) and Baseline pain intensity (last pain score measured within 10 minutes before dosing) 5 on an 11-point (0 to 10) pain intensity numerical rating scale (NRS).

Exclusion Criteria:

  • History of malignancy within the past 2 years
  • Current or history of alcohol or drug abuse.
  • Clinically relevant pulmonary, gastrointestinal, endocrine, metabolic, neurological, psychiatric disorders (resulting in disorientation, memory impairment or inability to report accurately
  • History of seizure disorder, epilepsy, or any condition that would put the subject at risk of seizures
  • Severely impaired renal function
  • Moderately or severely impaired hepatic function
  • Contraindications, or a history of allergy or hypersensitivity, to tapentadol, ibuprofen, or excipients
  • Use of prohibited concomitant medication, or not allowed use of restricted concomitant medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01435577

Locations
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Grünenthal GmbH
  More Information

No publications provided

Responsible Party: Grünenthal GmbH
ClinicalTrials.gov Identifier: NCT01435577     History of Changes
Other Study ID Numbers: 295054
Study First Received: September 15, 2011
Results First Received: March 5, 2013
Last Updated: June 24, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Grünenthal GmbH:
Bunionectomy
Postsurgical Pain
Acute Pain

Additional relevant MeSH terms:
Hallux Valgus
Foot Deformities
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on April 17, 2014